Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis

Effects of glucocorticoids and tumor necrosis factor-alpha inhibitors on both clinical and molecular parameters in patients with Takayasu arteritis

To explore the effect of sequential treatment with glucocorticoid and tumor necrosis factor-alpha inhibitors in patients with Takayasu arteritis (TA). In five patients with TA, the effects of the sequential treatment with prednisone for 5-7 months and then with adalimumab (ADA) + methotrexate (MTX)...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmacology & pharmacotherapeutics Vol. 5; no. 3; pp. 193 - 196
Main Authors: Serra, Raffaele, Grande, Raffaele, Buffone, Gianluca, Scarcello, Edoardo, Tripodi, Fabio, Rende, Pierandrea, Gallelli, Luca, de Franciscis, Stefano
Format: Journal Article
Language:English
Published: India Medknow Publications and Media Pvt. Ltd 01-07-2014
Sage Publications Ltd
Medknow Publications & Media Pvt Ltd
Subjects:
Agreements
Corticosteroids
Disease
Dosage and administration
Drug therapy
Heart attacks
Medical imaging
Plasma
Proteins
Research Paper
Takayasu's arteritis
Tumor necrosis factor inhibitors
methotrexate
matrix metalloproteinases-9
Adalimumab
neutrophil gelatinase-associated lipocalin
infliximab
takayasu arteritis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To explore the effect of sequential treatment with glucocorticoid and tumor necrosis factor-alpha inhibitors in patients with Takayasu arteritis (TA). In five patients with TA, the effects of the sequential treatment with prednisone for 5-7 months and then with adalimumab (ADA) + methotrexate (MTX) or infliximab + MTX, or with ADA only, for 12 months on both clinical and laboratory findings were evaluated. All treatments improved both symptoms and laboratory parameters without the development of side-effects. It was hypothesized that MMP-9 and neutrophil gelatinase-associated lipocalin could be markers of the response to the treatments.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0976-500X
0976-5018
DOI:10.4103/0976-500X.136101